First time available for research use


Pembrolizumab antibody from Keytruda®

Therapeutic PD-1-antibody from the original Keytruda® commercial drug targeting the PD-1-antigen, also referred to as Keytruda® or pembrolizumab antibody. Research-relevant quantities are available as licence-free consumable in aliquoted or diluted variant. Therapeutic monoclonal antibodies can be used from researchers in in vitro and in vivo experiments, biosimilar developers can order different batches at the same time.

Choose your antibody
Easy Access

Easy Access

Easy to order as license-free research consumable
Multiple batches

Multiple batches

Up to 10 batches of original drugs for examining batch-to-batch variations
Reduce costs

Reduce costs

Up to 80% less compared to the original pharmaceutical price
Prompt delivery

Prompt delivery

Shipment within days worldwide according to GDP-standards
Documented origin

Documented origin

Information on batch, registration number, expiry date, GDP-compliant pedigree

What our clients say

pembrolizumab / Keytruda

Product Reference

Drug nameKeytruda®
API typePembrolizumab is a humanised monoclonal anti-programmed cell death-1 (PD-1) antibody(IgG4/kappa isotype with a stabilising sequence alteration in the Fc region) produced in Chinese hamster ovary cells by recombinant DNA technology
Pharmacotherapeutic group
Antineoplastic agents, monoclonal antibodies
ATC code
Target of antibody
PD-1; Synonyms: CD279, PD1, SLEB2, hPD-1, hPD-l, Ly101, Pdc1
General function
Short description
Pharmacodynamic properties
(Mechanism of action; Source EMA document)
KEYTRUDA is a humanised monoclonal antibody which binds to the programmed cell death-1 (PD-1) receptor and blocks its interaction with ligands PD-L1 and PD-L2. The PD-1 receptor is a negative regulator of T-cell activity that has been shown to be involved in the control of T-cell immune responses. KEYTRUDA potentiates T-cell responses, including anti-tumour responses, through blockade of PD-1 binding to PD-L1 and PD-L2, which are expressed in antigen presenting cells and may be expressed by tumours or other cells in the tumour microenvironment.
Pharmacodynamic properties (Pharmacodynamic effects; Source EMA document)
Original license holder
Marketing authorisation numbers
EU/1/15/1024/001 - 002
Marketing authorisation holder
Merck Sharp & Dohme Limited
Hertford Road
Hertfordshire EN11 9BU
United Kingdom
Name of the manufacturer of the biological active substance
MedImmune, LL
C Frederick Manufacturing Center (FMC)
633/636/660 Research Court Frederick
MD 21703-8619, USA

Boehringer Ingelheim (BIB)
Pharma GmbH & Co. KG
Birkendorfer Straße 65
88397 Biberach an der Riss
Name and address of the manufacturer(s) responsible for batch releaseSchering-Plough Labo NV
Industriepark 30, Heist-op-den-Berg
B-2220, Belgium
Max shelf life
24 months
Storage conditions
2°C – 8°C
List of excipients
L-histidine hydrochloride monohydrate
Polysorbate 80